PTGX Profile
Protagonist Therapeutics Inc (PTGX) is a biopharmaceutical company focused on developing and commercializing peptide-based drugs to treat gastrointestinal and blood disorders, including inflammatory bowel disease, Crohn's disease, and beta-thalassemia. The company's lead drug candidate, PTG-300, is a synthetic peptide that targets hepcidin, a protein that regulates iron metabolism, to treat iron overload disorders. PTGX is also developing PTG-200, a drug candidate for treating inflammatory bowel disease, and other peptide-based drugs for various diseases.
PTGX uses its proprietary technology platform, called Protagonist Integrated Discovery Platform, to design and develop novel peptide-based drugs. The platform combines computational modeling, high-throughput screening, and structural biology to optimize peptide drug candidates for maximum potency, specificity, and stability. The company's strategy is to focus on developing drugs for diseases with high unmet medical needs, with the goal of bringing transformative therapies to patients.
As of September 2021, PTGX had a market capitalization of approximately $390 million.
|
